Clinical Trial Update: Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of decitabine, cedazuridine (ASTX727), and ASTX029 (an ERK inhibitor) for patients with RAS-pathway mutant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• ASTX029
• ASTX727 (cedazuridine/decitabine)
• Cedazuridine (Cedazuridine)
• Decitabine (Decitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm | Phase 1, Phase 2 | Status: WITHDRAWN